Results from preclinical in vivo vaccination studies showing that the PCI technology can significantly improve therapeutically relevant immune responses accepted for publication

Posted on Dec 12, 2013

Oslo, 3 December 2013 – PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that results from in vivo studies with PCI Biotech’s proprietary technology photochemical internalization (PCI) at University Hospital Zurich have been accepted for publication and is available online in Journal of Controlled Release, a high impact pharmaceutical scientific journal. The article has […]

Filing of patent applications for the PCI technology in vaccination

Posted on Dec 12, 2013

Oslo, 29 August 2013 – PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that it has filed several patent applications within the area of vaccines. These applications will give PCI Biotech the opportunity to obtain further patent protection for the use of the PCI technology in vaccination, supplementing the already granted and pending patents […]

Update on clinical studies – both clinical studies now open for patient inclusion.

Posted on Dec 12, 2013

Oslo, 27 June 2013 – PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that both the temporary paused intra-tumour part of the head & neck cancer study and the bile duct cancer study are open for inclusion and actively screening for patients. Head & Neck cancer Patient inclusion in the ENHANCE study in head […]